• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二次谐波产生的可量化纤维化参数为非酒精性脂肪性肝病的疾病进展和消退提供特征。

Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease.

作者信息

Ng Nicole, Tai Dean, Ren Yayun, Chng Elaine, Seneshaw Mulugeta, Mirshahi Faridoddin, Idowu Michael, Asgharpour Amon, Sanyal Arun J

机构信息

Virginia Commonwealth University School of Medicine, Richmond, VA, USA.

Histoindex Pte. Ltd, Singapore.

出版信息

Clin Pathol. 2023 Mar 26;16:2632010X231162317. doi: 10.1177/2632010X231162317. eCollection 2023 Jan-Dec.

DOI:10.1177/2632010X231162317
PMID:37008387
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10052491/
Abstract

INTRODUCTION

The current ordinal fibrosis staging system for nonalcoholic steatohepatitis (NASH) has a limited dynamic range. The goal of this study was to determine if second-harmonic generated (SHG) quantifiable collagen fibrillar properties (qFP) and their derived qFibrosis score capture changes in disease progression and regression in a murine model of NASH, in which disease progression can be induced by a high fat sugar water (HFSW) diet and regression by reversal to chow diet (CD).

METHODS

DIAMOND mice were fed a CD or HFSW diet for 40 to 52 weeks. Regression related changes were studied in mice with diet reversal for 4 weeks after 48 to 60 weeks of a HFSW diet.

RESULTS

As expected, mice on HFSW developed steatohepatitis with stage 2 to 3 fibrosis between weeks 40 and 44. Both the collagen proportionate area and the qFibrosis score based on 15 SHG-quantified collagen fibrillar properties in humans were significantly higher in mice on HFSW for 40 to 44 weeks compared to CD fed mice. These changes were greatest in the sinusoids (Zone 2) with further increase in septal and portal fibrosis related scores between weeks 44 and 48. Diet reversal led to decrease in qFibrosis, septal thickness, and cellularity with greatest changes in Zone 2. Specific qFPs associated with progression only, regression only, or both processes were identified and categorized based on direction of fibrosis change.

CONCLUSION

Complementing recent human studies, these findings support the concept that changes of disease progression and regression can be assessed using SHG-based image quantification of fibrosis related parameters.

摘要

引言

目前用于非酒精性脂肪性肝炎(NASH)的序数纤维化分期系统动态范围有限。本研究的目的是确定二次谐波产生(SHG)可量化的胶原纤维特性(qFP)及其衍生的q纤维化评分是否能捕捉NASH小鼠模型中疾病进展和消退的变化,在该模型中,高脂肪糖水(HFSW)饮食可诱导疾病进展,而恢复正常饮食(CD)可使疾病消退。

方法

将DIAMOND小鼠喂食CD或HFSW饮食40至52周。在HFSW饮食48至60周后,对饮食逆转4周的小鼠进行与消退相关的变化研究。

结果

正如预期的那样,喂食HFSW的小鼠在第40至44周出现了伴有2至3期纤维化的脂肪性肝炎。与喂食CD的小鼠相比,喂食HFSW 40至44周的小鼠中,基于人类15种SHG量化胶原纤维特性的胶原比例面积和q纤维化评分均显著更高。这些变化在肝血窦(2区)最为明显,在第44至48周期间,间隔和门脉纤维化相关评分进一步增加。饮食逆转导致q纤维化、间隔厚度和细胞密度降低,2区变化最大。根据纤维化变化方向,识别并分类了仅与进展、仅与消退或与两者过程相关的特定qFP。

结论

作为对近期人类研究的补充,这些发现支持了这样一种概念,即可以使用基于SHG图像对纤维化相关参数进行量化来评估疾病进展和消退的变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/412fe4dd2ff1/10.1177_2632010X231162317-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/c4611cf3498f/10.1177_2632010X231162317-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/f1452228851c/10.1177_2632010X231162317-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/809ec36eae0d/10.1177_2632010X231162317-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/2469833b79f5/10.1177_2632010X231162317-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/412fe4dd2ff1/10.1177_2632010X231162317-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/c4611cf3498f/10.1177_2632010X231162317-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/f1452228851c/10.1177_2632010X231162317-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/809ec36eae0d/10.1177_2632010X231162317-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/2469833b79f5/10.1177_2632010X231162317-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/789e/10052491/412fe4dd2ff1/10.1177_2632010X231162317-fig5.jpg

相似文献

1
Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease.二次谐波产生的可量化纤维化参数为非酒精性脂肪性肝病的疾病进展和消退提供特征。
Clin Pathol. 2023 Mar 26;16:2632010X231162317. doi: 10.1177/2632010X231162317. eCollection 2023 Jan-Dec.
2
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.借助人工智能分析的数字病理学能更深入地洞察非酒精性脂肪性肝炎(NASH)中治疗引起的纤维化消退情况。
J Hepatol. 2022 Nov;77(5):1399-1409. doi: 10.1016/j.jhep.2022.06.018. Epub 2022 Jun 30.
3
Second Harmonic Generation Reveals Subtle Fibrosis Differences in Adult and Pediatric Nonalcoholic Fatty Liver Disease.二次谐波产生揭示成人和儿童非酒精性脂肪性肝病中细微的纤维化差异。
Am J Clin Pathol. 2017 Nov 20;148(6):502-512. doi: 10.1093/ajcp/aqx104.
4
Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).成像肝纤维化在饮食诱导的非酒精性脂肪性肝炎(NASH)模型中。
Contrast Media Mol Imaging. 2019 Dec 1;2019:6298128. doi: 10.1155/2019/6298128. eCollection 2019.
5
Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease.肝活检在非酒精性脂肪性肝病肝纤维化定量评估中的应用。
Indian J Pathol Microbiol. 2021 Jun;64(Supplement):S104-S111. doi: 10.4103/IJPM.IJPM_947_20.
6
Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.通过肝活检追踪非酒精性脂肪性肝炎疾病的肥胖饮食诱导小鼠模型。
World J Hepatol. 2016 Jun 8;8(16):673-84. doi: 10.4254/wjh.v8.i16.673.
7
Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.肠道固醇调节元件结合蛋白2的过度激活会促进饮食诱导的非酒精性脂肪性肝炎。
Am J Physiol Gastrointest Liver Physiol. 2017 Nov 1;313(5):G376-G385. doi: 10.1152/ajpgi.00174.2017. Epub 2017 Aug 3.
8
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective.非酒精性脂肪性肝病肝纤维化定量评估的研究进展:组织学视角。
Clin Mol Hepatol. 2021 Jan;27(1):44-57. doi: 10.3350/cmh.2020.0181. Epub 2020 Nov 19.
9
Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models.与大泡性脂肪变性共定位的胶原蛋白能更好地区分非酒精性脂肪性肝病小鼠模型中的纤维化进展。
Front Med (Lausanne). 2023 Jun 2;10:1172058. doi: 10.3389/fmed.2023.1172058. eCollection 2023.
10
Quantitative fibrosis parameters highly predict esophageal-gastro varices in primary biliary cirrhosis.定量纤维化参数能高度预测原发性胆汁性肝硬化患者的食管胃静脉曲张。
Eur Rev Med Pharmacol Sci. 2016;20(6):1037-43.

引用本文的文献

1
Development of AI Based Fibrosis Detection Algorithm by SHG/TPEF Microscopy for Fully Quantified Liver Fibrosis Assessment in MASH.基于SHG/TPEF显微镜的人工智能纤维化检测算法的开发,用于MASH中完全量化的肝纤维化评估。
Liver Int. 2025 Sep;45(9):e70258. doi: 10.1111/liv.70258.
2
The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis.新型血管紧张素 II 型 2 受体(AT2)配体β - 脯氨酸 7 血管紧张素 III(β - Pro7 Ang III)在博来霉素诱导的肺纤维化小鼠中,诱导出与化合物 21 等效的抗纤维化作用,但比吡非尼酮具有更广泛的抗纤维化作用。
Clin Sci (Lond). 2025 Jul 31;139(14):809-824. doi: 10.1042/CS20245138.
3

本文引用的文献

1
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.借助人工智能分析的数字病理学能更深入地洞察非酒精性脂肪性肝炎(NASH)中治疗引起的纤维化消退情况。
J Hepatol. 2022 Nov;77(5):1399-1409. doi: 10.1016/j.jhep.2022.06.018. Epub 2022 Jun 30.
2
Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease.生成饮食诱导的非酒精性脂肪肝小鼠模型。
Methods Mol Biol. 2022;2455:19-30. doi: 10.1007/978-1-0716-2128-8_2.
3
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
Liver fibrosis progression analyzed with AI predicts renal decline.
通过人工智能分析的肝纤维化进展可预测肾功能衰退。
JHEP Rep. 2025 Feb 12;7(5):101358. doi: 10.1016/j.jhepr.2025.101358. eCollection 2025 May.
4
Mouse Models for the Study of Liver Fibrosis Regression and .用于肝纤维化消退研究的小鼠模型及…… (原文似乎不完整)
J Clin Transl Hepatol. 2024 Nov 28;12(11):930-938. doi: 10.14218/JCTH.2024.00212. Epub 2024 Oct 11.
5
Role of artificial intelligence in staging and assessing of treatment response in MASH patients.人工智能在MASH患者分期及治疗反应评估中的作用。
Front Med (Lausanne). 2024 Oct 21;11:1480866. doi: 10.3389/fmed.2024.1480866. eCollection 2024.
6
Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology.数字量化桥接纤维化和间隔可揭示常规组织学未见的自然史和治疗变化。
Liver Int. 2024 Dec;44(12):3214-3228. doi: 10.1111/liv.16092. Epub 2024 Sep 9.
7
AI Digital Pathology Using qFibrosis Shows Heterogeneity of Fibrosis Regression in Patients with Chronic Hepatitis B and C with Viral Response.使用qFibrosis的人工智能数字病理学显示慢性乙型和丙型肝炎病毒反应患者纤维化消退的异质性。
Diagnostics (Basel). 2024 Aug 22;14(16):1837. doi: 10.3390/diagnostics14161837.
8
Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.脂肪性肝炎中的数字病理学和空间组学:临床应用与发现潜力
Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000866.
9
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.人工智能辅助数字病理学在非酒精性脂肪性肝炎中的应用:现状与未来方向
J Hepatol. 2024 Feb;80(2):335-351. doi: 10.1016/j.jhep.2023.10.015. Epub 2023 Oct 24.
10
Digital pathology for nonalcoholic steatohepatitis assessment.数字病理学在非酒精性脂肪性肝炎评估中的应用。
Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):57-69. doi: 10.1038/s41575-023-00843-7. Epub 2023 Oct 3.
专家小组审查,以比较美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)关于非酒精性脂肪性肝炎药物开发及终点指标的指南
Gastroenterology. 2022 Mar;162(3):680-688. doi: 10.1053/j.gastro.2021.10.051. Epub 2021 Nov 23.
4
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.随机、对照试验研究泛 PPAR 激动剂 Lanifibranor 在 NASH 中的作用。
N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.
5
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.FALCON 项目:两项 2b 期随机、双盲、安慰剂对照研究,评估 Pegbelfermin 治疗非酒精性脂肪性肝炎伴桥接纤维化或代偿性肝硬化患者的疗效和安全性。
Contemp Clin Trials. 2021 May;104:106335. doi: 10.1016/j.cct.2021.106335. Epub 2021 Feb 28.
6
Therapeutic pipeline in nonalcoholic steatohepatitis.非酒精性脂肪性肝炎的治疗药物研发管线。
Nat Rev Gastroenterol Hepatol. 2021 Jun;18(6):373-392. doi: 10.1038/s41575-020-00408-y. Epub 2021 Feb 10.
7
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.纤维化分期与非酒精性脂肪性肝病患者结局的相关性:系统评价和荟萃分析。
Gastroenterology. 2020 May;158(6):1611-1625.e12. doi: 10.1053/j.gastro.2020.01.043. Epub 2020 Feb 4.
8
Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.西尼riviroc 治疗非酒精性脂肪性肝炎和纤维化的成年人:CENTAUR 研究 2b 期的最终分析。
Hepatology. 2020 Sep;72(3):892-905. doi: 10.1002/hep.31108. Epub 2020 Jul 21.
9
qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.qFIBS:一种用于非酒精性脂肪性肝炎患者纤维化、炎症、气球样变和脂肪变性定量评估的自动化技术。
Hepatology. 2020 Jun;71(6):1953-1966. doi: 10.1002/hep.30986. Epub 2020 May 7.
10
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD.非酒精性脂肪性肝病临床试验终点的 AASLD/EASL 联合研讨会报告。
J Hepatol. 2019 Oct;71(4):823-833. doi: 10.1016/j.jhep.2019.04.019. Epub 2019 Jul 9.